Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106349 | 0.82 | MAPT (0.54) | MAPTTDP1SIGMAR1SCN2ANPC1 | |
| SCHEMBL6774952 | 0.81 | MAPT (0.55) | MAPTTDP1SIGMAR1SCN2ANPC1 | |
| SCHEMBL6769990 | 0.81 | MAPT (0.62) | MAPTTDP1SIGMAR1SCN2ANPC1 | |
| SCHEMBL6768080 | 0.80 | MAPT (0.52) | MAPTTDP1SIGMAR1SCN2ANPSR1 | |
| SCHEMBL9059194 | 0.80 | SIGMAR1 (0.61) | MAPTSIGMAR1NPC1LMNAHTT | |
| SCHEMBL6768946 | 0.78 | SIGMAR1 (0.57) | MAPTTDP1SIGMAR1SCN2ANPSR1 | |
| SCHEMBL6776139 | 0.78 | MAPT (0.56) | MAPTTDP1SIGMAR1SCN2ANPSR1 | |
| SCHEMBL7098716 | 0.77 | MAPT (0.55) | MAPTTDP1SIGMAR1SCN2ANPSR1 | |
| SCHEMBL7099591 | 0.77 | ALDH1A1 (0.55) | MAPTTDP1SIGMAR1SCN2ANPC1 | |
| SCHEMBL7105253 | 0.77 | MAPT (0.52) | MAPTTDP1SIGMAR1SCN2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2003-08-14 | — | — | US | claimed |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2002-07-25 | — | — | US | claimed |
| US-6358993-B1 | TREATMENT OF NEUROLOGICAL INJURY AND NEURODEGENERATIVE DISORDERS; NEUROPROTECTIVE AGENTS; SUBSTITUTED INDOLINYL AND INDOLINYL GUANIDINE DERIVATIVES | CENES PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| EP-0925300-A4 | — | — | 1999-06-30 | — | — | EP | claimed |
| EP-0925300-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-30 | — | — | EP | claimed |
| WO-1997030054-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | MAPT 122/4885TDP1 297/4885SIGMAR1 2813/4885 |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | MAPT 122/4885TDP1 297/4885SIGMAR1 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.